Package 31722-506-05

{"route": ["ORAL"], "spl_id": "e8ca069d-b3f8-35bf-e053-2a95a90a0699", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "upc": ["0331722506052", "0331722506601"], "unii": ["2T8Q726O95", "4B9XT59T7S"], "rxcui": ["200082"], "spl_set_id": ["f80bd0f3-47eb-4b82-a633-4536cf376cf6"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Camber Pharmaceuticals, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "500 TABLET, FILM COATED in 1 BOTTLE (31722-506-05)", "package_ndc": "31722-506-05", "marketing_start_date": "20150918"}, {"sample": false, "description": "60 TABLET, FILM COATED in 1 BOTTLE (31722-506-60)", "package_ndc": "31722-506-60", "marketing_start_date": "20150918"}], "brand_name": "LAMIVUDINE and ZIDOVUDINE", "product_id": "31722-506_e8ca069d-b3f8-35bf-e053-2a95a90a0699", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "31722-506", "generic_name": "LAMIVUDINE and ZIDOVUDINE", "labeler_name": "Camber Pharmaceuticals, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "LAMIVUDINE and ZIDOVUDINE", "active_ingredients": [{"name": "LAMIVUDINE", "strength": "150 mg/1"}, {"name": "ZIDOVUDINE", "strength": "300 mg/1"}], "application_number": "ANDA079124", "marketing_category": "ANDA", "marketing_start_date": "20150918", "listing_expiration_date": "20261231"}